Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 36

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 36
---
 such event.

| 21 |

Rights Offerings; pro rata distributions. If we issue Ordinary Share equivalents or rights to purchase shares, warrants, securities or other
property pro rata to holders of Depositary Shares, a holder of a warrant will be entitled to acquire, subject to the beneficial ownership
limitation described above, such securities or property that such holder could have acquired if such holder had held the number of Depositary
Shares issuable upon complete exercise of the warrant immediately prior to the date a record is taken for such issuance. If we declare
or make any dividend or other distribution of assets or rights to acquire assets to holders of Depositary Shares or Ordinary Shares,
a holder of a warrant will be entitled to participate, subject to the beneficial ownership limitation, in such distribution to the same
extent that the holder would have participated therein if the holder had held the number of Depositary Shares issuable upon full exercise
of the warrant.

Fundamental Transaction. If we effect a fundamental transaction, including, among other things, a merger, sale of substantially all of our assets,
tender offer, exchange offer and other business combination transactions, then upon any subsequent exercise of a warrant, the holder
thereof shall have the right to receive, for each Ordinary Share represented by the Depositary Shares that would have been issuable upon
such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor’s or acquiring
corporation’s securities, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental
transaction by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately
prior to such fundamental transaction. In addition, in the event of a fundamental transaction that is (i) an all cash or substantially
all cash transaction, (ii) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (iii) with certain
limited exceptions, a fundamental transaction involving a person or entity not traded on a national securities exchange or other established
trading market, including, but not limited to, the London Stock Exchange, AIM, The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ
Global Select Market, The NASDAQ Global Market, The NASDAQ Capital Market, the OTC QX, the OTC QB or the Over-the-Counter Bulletin Board,
then the Company or any successor entity will pay